Spots Global Cancer Trial Database for A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Official Title: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Study ID: NCT03517488
Conditions
Interventions
Study Description
Brief Summary: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
UCLA Hematology-Oncology Clinic (Westwood), Los Angeles, California, United States
University of California San Diego Moores Cancer Center, San Diego, California, United States
University of California San Francisco Medical Center, San Francisco, California, United States
Emory University, Atlanta, Georgia, United States
University of Chicago Medicine, Chicago, Illinois, United States
The University of Kansas Clinical Research Center, Fairway, Kansas, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
Providence Portland Medical Center, Portland, Oregon, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Contact Details
Name: Zequn Tang, MD
Affiliation: Xencor, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
